In case you missed it, health reporters who cover medical studies had a shining moment recently. It centered around the heavily stage-managed publication of the Trial to Assess Chelation Therapy, or TACT.
TACT was a 10-year double-blind, randomized controlled study of 1,708 patients that was carried out at 134 sites in the U.S. and Canada. It cost the government and, by extension, taxpayers, $31 million. About 60 percent of the sites were traditional chelation centers – some of which had shaky legal histories, the rest were traditional cardiology practices and academic medical centers, including Johns Hopkins Bayview Medical Center and the Mayo Clinic. Continue reading